IP Library Granted Patent US 10,774,065
Granted Patent B2
US 10,774,065 · App. 16/117,674 · Granted Sep 15, 2020

1-pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and compositions thereof for inhibiting the activity of SHP2

Inventors: Christine Hiu-Tung Chen (Waltham, MA); Zhuoliang Chen (Belmont, MA); Jorge Garcia Fortanet (Wilmington, MA); Denise Grunenfelder (Pasadena, CA); Rajesh Karki (Quincy, MA); Mitsunori Kato (Cambridge, MA); Matthew J. LaMarche (Reading, MA); Lawrence Blas Perez (Silver Springs, MD); Travis Matthew Stams (Stow, MA); Sarah Williams (Emeryville, CA)
Assignee: NOVARTIS AG
C07D401/04C07D239/48C07D241/26C07D249/14C07D401/14C07D403/04C07D409/14C07D471/04C07D487/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,774,065
App. No.
16/117,674
Granted
Sep 15, 2020
Kind
B2
Abstract

The present invention relates to compounds of formula I: in which m, Y 1 , Y 2 , Y 3 , R 1 , R 2a , R 2b , R 3a , R 3b , R 4a , R 4b , R 5a and R 5b are defined in the Summary of the Invention; capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.

Claims (13)

1. A compound of formula Ic:

in which:

n is selected from 1, 2, 3, 4 and 5;

Y 1 is selected from CH and N;

Y 2 is CR 6 ;

R 3a is selected from C 1-4 alkyl, C 1-4 alkoxy, amino, hydroxy, C 3-8 cycloalkyl and C 1-4 alkyl-amino;

R 4a is selected from hydrogen, C 1-4 alkyl, C 1-4 alkoxy, amino, hydroxy, C 3-8 cycloalkyl and C 1-4 alkyl-amino;

R 6 is selected from hydrogen, halo and methyl;

R 9 is selected from halo, amino, hydroxy, N 3 , C 1-4 alkyl, halo-substituted-C 1-4 alkyl, C 1-4 alkoxy, —C(O)OR 10 and —NHC(O)R 10 ;

R 10 is selected from hydrogen, phenyl and naphthyl; wherein said phenyl of R 13 is unsubstituted or substituted with methoxy; or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

3. A pharmaceutical composition comprising a compound of claim 1 or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 13, 2018
From: CHEN, CHRISTINE HIU-TUNG; CHEN, ZHUOLIANG; FORTANET, JORGE GARCIA; KARKI, RAJESH; KATO, MITSUNORI; LAMARCHE, MATTHEW J.; PEREZ, LAWRENCE BLAS; STAMS, TRAVIS MATTHEW; WILLIAMS, SARAH
To: NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC.
Reel/Frame 046861/0839 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 13, 2018
From: GRUNENFELDER, DENISE
To: NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC.
Reel/Frame 046861/0888 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 13, 2018
From: NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC.
To: NOVARTIS AG
Reel/Frame 046861/0974 →
Continuity (3)
Continuation 15110498
Provisional Application 61928738 · Jan 17, 2014
Related Publication 20180362496A1 · Dec 20, 2018